Weekly Pharma & Life Science News Round-Up: 16th – 20th January 2023

Written by: Lucy Walters
Published on: 20 Jan 2023

Weekly Life Science News Round-UpA round-up of the latest news from the Pharma & Life Science industry; including news from the Pharmaceutical, Clinical Research, Biotechnology and Medical Device sectors from 16th – 20th January 2023.

PharmiWeb.Jobs Welcomes Alexion

PharmiWeb.Jobs is delighted to welcome Alexion to its job board. Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with severe and life-threatening rare disorders.

Acquisition of Neogene Therapeutics Completed

AstraZeneca has completed the acquisition of Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and manufacturing of next-generation T-cell receptor therapies (TCR-Ts).

Sanofi Launches First Global Scholarship Programme for Students from Underrepresented Communities Pursuing Careers in Healthcare

Sanofi announces at the 53rd Annual Meeting of the World Economic Forum in Davos the launch of the Sanofi NextGen Scholarship, its first global higher education scholarship programme for people from numerous communities underrepresented in healthcare professions.

Cryoport Announces New Strategic Partnership with Syneos Health to Advance Cell & Gene Therapies

Cryoport, Inc. announces a new strategic partnership with Syneos Health® (NASDAQ: SYNH), the only fully integrated biopharmaceutical solutions organization purpose-built to accelerate customer success.

Roche’s Tecentriq plus Avastin is the first treatment combination to reduce the risk of cancer returning in people with certain types of early-stage liver cancer in a Phase III trial

Roche (SIX: RO, ROG; OTCQX: RHHBY) announces that the Phase III IMbrave050 study met its primary endpoint of recurrence-free survival (RFS) at the prespecified interim analysis.

EverImmune Launches Phase I Clinical Trial for its Oncobiotic Drug Candidate in Lung and Kidney Cancer

EverImmune, a clinical-stage biotechnology company specialized in the development of live biotherapeutic products in the field of microbiota oncology, announces that a first patient has been treated in its phase I clinical trial (EV 2101) evaluating Oncobax® AK in lung and kidney cancer patients.

Upperton Pharma Solutions Breaks Ground on New Nottingham Based Development and Manufacturing Facility

Upperton Pharma Solutions, a leading UK contract development and manufacturing organisation (CDMO), is delighted to announce that it has begun construction work for its new Development and GMP Manufacturing headquarters in Nottingham, UK.

AC Immune Partner Life Molecular Imaging Initiates Phase 3 Study of Tau PET Diagnostic PI-2620 for Alzheimer’s Disease

AC Immune SA (NASDAQ: ACIU) announces that its collaboration partner, Life Molecular Imaging (LMI), has imaged the first patient in ADvance, the pivotal Phase 3 trial of PI-2620, a Tau PET (positron emission tomography) imaging agent for AD (Alzheimer’s disease).

TrakCel and AmerisourceBergen Expand Platform Integration to Facilitate Patient Care Coordination for Cell and Gene Therapies

TrakCel and AmerisourceBergen have expanded their platform integration capabilities to provide physicians and patient services teams more complete visibility across the treatment development and patient journey, enabling seamless care coordination and timely patient engagement.

NeoPhore Completes Extension to Series B Financing to Further Advance Discovery Pipeline

NeoPhore Limited, a small molecule neoantigen immuno-oncology company, announces the completion of its £21.5m (US $28.5m) Series B financing, with a £6m (US $7.5m) financing extension.